Doxorubicin liposome: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
mNo edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage01
{{DrugProjectFormSinglePage01
|genericName=Doxorubicin liposome
 
|aOrAn=an
|authorTag=
|drugClass=anthracycline
 
|indicationType=treatment
<!--Overview-->
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Doxorubicin liposome in adult patients.
 
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Doxorubicin liposome in adult patients.
|genericName=
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Doxorubicin liposome in pediatric patients.
 
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Doxorubicin liposome in pediatric patients.
genericname
|clinicalTrials=There is limited information regarding <i>Clinical Trials Experience</i> of Doxorubicin liposome in the drug label.
 
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of Doxorubicin liposome in the drug label.
|aOrAn=
|useInLaborDelivery=There is no FDA guidance on the use of Doxorubicin liposome during labor and delivery.
 
|useInNursing=There is no FDA guidance on the use of Doxorubicin liposome with respect to nursing mothers.
a
|useInPed=There is no FDA guidance on the use of Doxorubicin liposome with respect to pediatric patients.
 
|useInGeri=There is no FDA guidance on the use of Doxorubicin liposome with respect to geriatric patients.
|drugClass=
|useInGender=There is no FDA guidance on the use of Doxorubicin liposome with respect to specific gender populations.
 
|useInRace=There is no FDA guidance on the use of Doxorubicin liposome with respect to specific racial populations.
drugclass
|useInRenalImpair=There is no FDA guidance on the use of Doxorubicin liposome in patients with renal impairment.
 
|useInHepaticImpair=There is no FDA guidance on the use of Doxorubicin liposome in patients with hepatic impairment.
|indicationType=
|useInReproPotential=There is no FDA guidance on the use of Doxorubicin liposome in women of reproductive potentials and males.
 
|useInImmunocomp=There is no FDA guidance on the use of Doxorubicin liposome in patients who are immunocompromised.
treatment
|monitoring=There is limited information regarding <i>Monitoring</i> of Doxorubicin liposome in the drug label.
 
|PD=There is limited information regarding <i>Pharmacodynamics</i> of Doxorubicin liposome in the drug label.
|indication=
|PK=There is limited information regarding <i>Pharmacokinetics</i> of Doxorubicin liposome in the drug label.
 
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of Doxorubicin liposome in the drug label.
indication
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of Doxorubicin liposome in the drug label.
 
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of Doxorubicin liposome in the drug label.
|adverseReactions=
|alcohol=Alcohol-Doxorubicin liposome interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
|brandNames=®
commonadversereactions
|lookAlike=A® — B®
 
<!--Black Box Warning-->
 
|hasBlackBoxWarning=
 
Yes
 
|blackBoxWarningTitle=
 
<span style="color:#FF0000;">ConditionName</span>
 
|blackBoxWarningBody=
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
====Indications====
 
 
 
====Dosage====
 
 
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
<SMALL>There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.</SMALL>
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
<SMALL>There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.</SMALL>
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
====Indications====
 
 
 
====Dosage====
 
 
 
<SMALL>There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.</SMALL>
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
<SMALL>There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.</SMALL>
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
<SMALL>There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.</SMALL>
 
<!--Contraindications-->
 
|contraindications=
 
* Content
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
<SMALL>There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
<SMALL>There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
 
* '''Pregnancy Category: ABCDXN'''
 
:* Description
 
|useInPregnancyAUS=
 
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
<SMALL>There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.</SMALL>
 
|useInLaborDelivery=
 
<SMALL>There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.</SMALL>
 
|useInNursing=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.</SMALL>
 
|useInPed=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.</SMALL>
 
|useInGeri=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.</SMALL>
 
|useInGender=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.</SMALL>
 
|useInRace=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.</SMALL>
 
|useInRenalImpair=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.</SMALL>
 
|useInHepaticImpair=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.</SMALL>
 
|useInReproPotential=
 
<SMALL>There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.</SMALL>
 
|useInImmunocomp=
 
<SMALL>There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.</SMALL>
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
* Intravenous
 
|monitoring=
 
* Description
 
<SMALL>There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--IV Compatibility-->
 
|IVCompat=
 
<SMALL>There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Overdosage-->
 
|overdose=
 
* Description
 
<SMALL>There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
drugbox2
 
<!--Mechanism of Action-->
 
|mechAction=
 
mechanismofaction
 
<!--Structure-->
 
|structure=
 
[[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
<SMALL>There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Pharmacokinetics-->
 
|PK=
 
<SMALL>There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
<SMALL>There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Clinical Studies-->
 
|clinicalStudies=
 
<SMALL>There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--How Supplied-->
 
|howSupplied=
 
* Description
 
<SMALL>There is limited information regarding <i>How Supplied</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Package Label-->
 
|packLabel=
 
[[File:XXXXX.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
[[File:XXXXX.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
 
<!--Patient Counseling Information-->
 
|fdaPatientInfo=
 
<SMALL>There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.</SMALL>
 
<!--Precautions with Alcohol-->
 
|alcohol=
 
<SMALL>Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.</SMALL>
 
<!--Brand Names-->
 
|brandNames=
 
brandname
 
<!--Look-Alike Drug Names-->
 
|lookAlike=
 
<!--Drug Shortage Status-->
 
|drugShortage=
 
}}
}}
<!--Category-->
[[Category:Drug]]

Revision as of 17:59, 25 February 2015

Doxorubicin liposome
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

For patient information regarding genericname, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning
ConditionName
See full prescribing information for complete Boxed Warning.
* Content

Overview

Doxorubicin liposome is a drugclass that is FDA approved for the treatment of indication. There is a Black Box Warning for this drug as shown here. Common adverse reactions include commonadversereactions.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage

There is limited information regarding Off-Label Guideline-Supported Use of Doxorubicin liposome in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage

There is limited information regarding Off-Label Non–Guideline-Supported Use of Doxorubicin liposome in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications

Dosage

There is limited information regarding FDA-Labeled Use of Doxorubicin liposome in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage

There is limited information regarding Off-Label Guideline-Supported Use of Doxorubicin liposome in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage

There is limited information regarding Off-Label Non–Guideline-Supported Use of Doxorubicin liposome in pediatric patients.

Contraindications

  • Content

Warnings

  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Doxorubicin liposome in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Doxorubicin liposome in the drug label.

Drug Interactions

  • Description

Use in Specific Populations

Pregnancy

  • Pregnancy Category: ABCDXN
  • Description

Labor and Delivery

There is no FDA guidance on use of Doxorubicin liposome during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Doxorubicin liposome with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Doxorubicin liposome with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Doxorubicin liposome with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Doxorubicin liposome with respect to specific gender populations.

Race

There is no FDA guidance on the use of Doxorubicin liposome with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Doxorubicin liposome in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Doxorubicin liposome in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Doxorubicin liposome in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Doxorubicin liposome in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

  • Description

There is limited information regarding Monitoring of Doxorubicin liposome in the drug label.

Overdosage

  • Description

There is limited information regarding Chronic Overdose of Doxorubicin liposome in the drug label.

Pharmacology

drugbox2

Mechanism of Action

mechanismofaction

Structure

File:Doxorubicin liposome01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Doxorubicin liposome in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Doxorubicin liposome in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Doxorubicin liposome in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Doxorubicin liposome in the drug label.

How Supplied

  • Description

There is limited information regarding How Supplied of Doxorubicin liposome in the drug label.

Images

Package and Label Display Panel

File:XXXXX.png
This image is provided by the National Library of Medicine.
File:XXXXX.png
This image is provided by the National Library of Medicine.

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Doxorubicin liposome in the drug label.

Precautions with Alcohol

Alcohol-Doxorubicin liposome interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

brandname

Look-Alike Drug Names

Drug Shortage Status

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Doxorubicin_liposome&oldid=1073443"